Post by JHam on Jul 16, 2014 14:25:25 GMT
Tonix Pharmaceuticals Holding Corp. ("TONIX" or the "Company") is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves the quality of sleep in patients with chronic pain syndromes.
TONIX’s lead product is designed to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX’s products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses.
The Company’s most advanced product candidate, sublingual TNX-102 (TNX-102 SL) for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), is a novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. In September 2013, Tonix began enrollment in a pivotal trial of TNX-102 SL for the treatment of FM and is expected to enter a Phase 2 trial in 2014 for the treatment of PTSD.
TONIX’s lead product is designed to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments. TONIX’s products are the result of a program to harvest advances in science and medicine to search for potential therapeutic solutions among known pharmaceutical agents. TONIX is developing new formulations that have been optimized for new therapeutic uses.
The Company’s most advanced product candidate, sublingual TNX-102 (TNX-102 SL) for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), is a novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. In September 2013, Tonix began enrollment in a pivotal trial of TNX-102 SL for the treatment of FM and is expected to enter a Phase 2 trial in 2014 for the treatment of PTSD.